z-logo
Premium
Biochemical nutritional parameters in patients suffering from head and neck cancer after the administration of nutritional support. Preliminary study.
Author(s) -
Casbarien Octavio,
Cresta Pablo,
Silva Carolina,
Feliu Maria Susana,
Badia A,
DELGADO N LÓPEZ,
Perman Mario,
Navigante Alfredo,
Slobodianik Nora
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.864.3
Subject(s) - radial immunodiffusion , medicine , transferrin , head and neck cancer , gastroenterology , cancer , transthyretin , immunology , antibody
The evaluation of nutritional status, through biochemical parameters, in a subgroup of these patients, before and after oral intake of a nutritional supplement. Seven adult patients, were attended in the A. Roffo Institute, with local advanced head and neck cancer, underwent therapy with chemoradiotherapy that completed oral intake of a nutritional supplement, during 60 days (Supportan ® , Fresenius‐Kabi ). The supplement provides 500Kcal/day, P%27, F%40 (2 g EPA provided by fish oil, MCT and vegetal oils) and 33% of carbohydrates. Blood samples were collected from patients before(To) and after (Tf) the oral administration of the supplement plus habitual diet. Specific serum protein fractions:TTR, transferrin, C3c, C4c, Cp, Hp and PCR were measured by single radial immunodiffusion technique(Biocientífica SA, Argentina and Binding Site, UK). Results Tf vs To (mg/dl), expressed as X (SD) were:TTR:21.1(8.9) vs 22.9(7.3); Transferrin:188.9(36.1) vs 207.3 (20.9) ;C3c :122.6(24.9) vs 122.5(52.3);C4c:37.5( 7.4) vs 38.9 (11.1); Cp: 40.0 (6.7) vs 36.1(11.7), Hp: 334.0(194.2) vs 245.6(103.9); PCR : 1.4( 0.3) vs 1.6(2.1). No differences between Tf and To were observed. Data suggest that the administration of this oral supplement was useful to maintain the initial biochemical nutritional profile. Supported by UBA( 20020100100044)

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here